Ascentage Pharma Group International
OTC:ASPHF

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
OTC:ASPHF
Watchlist
Price: 8.48 USD Market Closed
Market Cap: 2.7B USD

Operating Margin

-263.6%
Current
Declining
by 38.6%
vs 3-y average of -225%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-263.6%
=
Operating Income
¥-1.2B
/
Revenue
¥390.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-263.6%
=
Operating Income
$-1.2B
/
Revenue
¥390.6m

Peer Comparison

Country Company Market Cap Operating
Margin
CN
Ascentage Pharma Group International
HKEX:6855
17.3B HKD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.5B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 96% of companies in China
Percentile
4th
Based on 8 544 companies
4th percentile
-263.6%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

Ascentage Pharma Group International
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

Ascentage Pharma Group International, a biopharmaceutical company stepping confidently onto the global stage, is driven by a mission to address unmet medical needs in the challenging realm of apoptosis-targeted therapies. Founded in 2009, with roots in both China and the United States, the company has honed its expertise in developing innovative small-molecule therapeutics. Its focus is on diseases inadequately treated by current standards, particularly cancers, hepatitis B, and age-related diseases. By concentrating on inhibiting protein-protein interactions that govern apoptosis, Ascentage Pharma employs sophisticated science to guide its research and development programs. This strategic focus on apoptosis, the programmed cell death process, enables the company to work on promising drug candidates that specifically target the pathways responsible for the survival and proliferation of malignant cells. Revenue generation for Ascentage Pharma is multi-faceted. Primarily, the company earns through partnerships, milestone payments, collaborative agreements, and licensing deals with larger pharmaceutical firms eager to leverage its unique expertise in apoptosis. In addition, its robust pipeline—comprising compounds at various stages of clinical development—provides strategic opportunities for monetization through out-licensing agreements once promising clinical data is established. By creating a symbiotic relationship with its partners, while also advancing its proprietary drug candidates towards commercialization, Ascentage Pharma not only progresses its significant research but also solidifies its financial foundation. The company’s growth is anchored in its ability to translate groundbreaking science into viable treatments that can crucially impact patients’ lives, paving a path to sustained financial and innovative success.

ASPHF Intrinsic Value
12.34 USD
Undervaluation 31%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-263.6%
=
Operating Income
¥-1.2B
/
Revenue
¥390.6m
What is Ascentage Pharma Group International's current Operating Margin?

The current Operating Margin for Ascentage Pharma Group International is -263.6%, which is below its 3-year median of -225%.

How has Operating Margin changed over time?

Over the last 3 years, Ascentage Pharma Group International’s Operating Margin has increased from -735.8% to -263.6%. During this period, it reached a low of -735.8% on Jun 30, 2022 and a high of -34% on Jun 30, 2024.

Back to Top